Literature DB >> 19735756

Resistance to mycobacterial infection: a pattern of early immune responses leads to a better control of pulmonary infection in C57BL/6 compared with BALB/c mice.

John Arko-Mensah1, Muhammad J Rahman, Irene R Dégano, Olga D Chuquimia, Agathe L Fotio, Irene Garcia, Carmen Fernández.   

Abstract

In this study, we have compared the immunological responses associated with early pulmonary mycobacterial infection in two mouse strains, BALB/c and C57BL/6 known to exhibit distinct differences in susceptibility to infection with several pathogens. We infected mice via the intranasal route. We have demonstrated that BALB/c was less able to control mycobacterial growth in the lungs during the early phase of pulmonary infection. Our results showed that during the early phase (day 3 to week 1), BALB/c mice exhibited a delay in the production of TNF and IFN-gamma in the lungs compared to C57BL/6 mice. Levels of IL-12 and soluble TNF receptors (sTNFR) were comparable between the mouse strains. The cellular subset distribution in these mice before and after infection showed a higher increase in CD11b+ cells in the lungs of C57BL/6, compared to BALB/c as early as day 3 postinfection. At early time points, higher levels of monocyte chemoattractant protein (MCP)-1 and macrophage inflammatory protein 1 (MIP)-alpha were detected in C57BL/6 than BALB/c mice. In vitro, BCG-infected bone marrow derived macrophages (BMM) from both mouse strains displayed similar capacities to either phagocytose bacteria or produce soluble mediators such as TNF, IL-12 and nitric oxide (NO). Although IFN-gamma stimulation of infected BMM in both mouse strains resulted in the induction of antimycobacterial activity, BALB/c mice had a reduced capacity to kill ingested bacteria. The above observations indicate that the chain of early, possibly innate immunological events occurring during pulmonary mycobacterial infection may directly impact on increased susceptibility or resistance to infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735756     DOI: 10.1016/j.vaccine.2009.06.110

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Histamine induces chemotaxis and phagocytosis in murine bone marrow-derived macrophages and RAW 264.7 macrophage-like cells via histamine H4-receptor.

Authors:  Christoph P Czerner; Andreas Klos; Roland Seifert; Detlef Neumann
Journal:  Inflamm Res       Date:  2013-12-08       Impact factor: 4.575

2.  CD11c(+)  CD103(+) cells of Mycobacterium tuberculosis-infected C57BL/6 but not of BALB/c mice induce a high frequency of interferon-γ- or interleukin-17-producing CD4(+) cells.

Authors:  Cássia A Sérgio; Thais B Bertolini; Ana Flávia Gembre; Rafael Q Prado; Vânia L D Bonato
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

3.  PPE38 Protein of Mycobacterium tuberculosis Inhibits Macrophage MHC Class I Expression and Dampens CD8+ T Cell Responses.

Authors:  Lu Meng; Jingfeng Tong; Hui Wang; Chengwu Tao; Qinglan Wang; Chen Niu; Xiaoming Zhang; Qian Gao
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

4.  Early Resistance of Non-virulent Mycobacterial Infection in C57BL/6 Mice Is Associated With Rapid Up-Regulation of Antimicrobial Cathelicidin Camp.

Authors:  Lucille Adam; Moisés López-González; Albin Björk; Sandra Pålsson; Candice Poux; Marie Wahren-Herlenius; Carmen Fernández; Anna-Lena Spetz
Journal:  Front Immunol       Date:  2018-09-03       Impact factor: 7.561

5.  In-vivo expressed Mycobacterium tuberculosis antigens recognised in three mouse strains after infection and BCG vaccination.

Authors:  Marta Romano; Tom H M Ottenhoff; Mariateresa Coppola; Fabienne Jurion; Susan J F van den Eeden; Hermann Giresse Tima; Kees L M C Franken; Annemieke Geluk
Journal:  NPJ Vaccines       Date:  2021-06-03       Impact factor: 7.344

6.  Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work?

Authors:  Diego L Costa; Eduardo P Amaral; Sivaranjani Namasivayam; Lara R Mittereder; Bruno B Andrade; Alan Sher
Journal:  Front Cell Infect Microbiol       Date:  2021-06-21       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.